Premium
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
Author(s) -
Razavi Homie,
ElKhoury Antoine C.,
Elbasha Elamin,
Estes Chris,
Pasini Ken,
Poynard Thierry,
Kumar Ritesh
Publication year - 2013
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.26218
Subject(s) - medicine , hepatology , hepatocellular carcinoma , hepatitis c virus , hepatitis c , life expectancy , incidence (geometry) , liver disease , liver transplantation , cirrhosis , disease burden , chronic liver disease , disease , immunology , transplantation , environmental health , virus , population , physics , optics
Hepatitis C virus (HCV) infection is a leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. A better understanding of HCV disease progression and the associated cost can help the medical community manage HCV and develop treatment strategies in light of the emergence of several potent anti‐HCV therapies. A system dynamic model with 36 cohorts was used to provide maximum flexibility and improved forecasting. New infections incidence of 16,020 (95% confidence interval, 13,510‐19,510) was estimated in 2010. HCV viremic prevalence peaked in 1994 at 3.3 (2.8‐4.0) million, but it is expected to decline by two‐thirds by 2030. The prevalence of more advanced liver disease, however, is expected to increase, as well as the total cost associated with chronic HCV infection. Today, the total cost is estimated at $6.5 ($4.3‐$8.4) billion and it will peak in 2024 at $9.1 ($6.4‐$13.3) billion. The lifetime cost of an individual infected with HCV in 2011 was estimated at $64,490. However, this cost is significantly higher among individuals with a longer life expectancy. Conclusion: This analysis demonstrates that US HCV prevalence is in decline due to a lower incidence of infections. However, the prevalence of advanced liver disease will continue to increase as well as the corresponding healthcare costs. Lifetime healthcare costs for an HCV‐infected person are significantly higher than for noninfected persons. In addition, it is possible to substantially reduce HCV infection through active management. (H EPATOLOGY 2013;57:2164–2170)